| 000 | 01775 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514071807.0 | ||
| 264 | 0 | _c20040408 | |
| 008 | 200404s 0 0 eng d | ||
| 022 | _a0914-8779 | ||
| 024 | 7 |
_a10.1007/s00774-003-0412-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKitatani, Kayoko | |
| 245 | 0 | 0 |
_aClinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy. _h[electronic resource] |
| 260 |
_bJournal of bone and mineral metabolism _c2003 |
||
| 300 |
_a217-24 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAlkaline Phosphatase _xanalysis |
| 650 | 0 | 4 |
_aAmino Acids _xmetabolism |
| 650 | 0 | 4 |
_aBiomarkers _xanalysis |
| 650 | 0 | 4 |
_aBone Density _xdrug effects |
| 650 | 0 | 4 | _aChromatography, High Pressure Liquid |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 |
_aEtidronic Acid _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOsteocalcin _xanalysis |
| 650 | 0 | 4 |
_aOsteoporosis, Postmenopausal _xdrug therapy |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aROC Curve |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aNakatsuka, Kiyoshi | |
| 700 | 1 | _aNaka, Hiroshi | |
| 700 | 1 | _aMiki, Takami | |
| 700 | 1 | _aMorii, Hirotoshi | |
| 700 | 1 | _aNishizawa, Yoshiki | |
| 773 | 0 |
_tJournal of bone and mineral metabolism _gvol. 21 _gno. 4 _gp. 217-24 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00774-003-0412-z _zAvailable from publisher's website |
| 999 |
_c12595515 _d12595515 |
||